Requesting Ebola Vaccine Doses

What to know

ERVEBO® is the only FDA-approved vaccine to prevent Ebola disease caused by infection with Ebola virus (species Orthoebolavirus zairense only). It is not planned for commercial marketing. It is maintained in the U.S. Strategic National Stockpile, with vaccine access within the United States facilitated by the U.S. government. The Centers for Disease Control and Prevention (CDC) will provide ERVEBO® when requested by licensed healthcare providers from institutions or sites with patients who meet the eligibility criteria to receive ERVEBO®.

Requesting initial ERVEBO® doses

Licensed healthcare providers who need to request initial doses of the ERVEBO® Ebola vaccine should:

  1. Ensure patient(s) who would receive ERVEBO® meet the eligibility criteria.
  2. Send an email to spathvax@cdc.gov with subject line: Request for ERVEBO.
    1. The CDC Ebola Vaccine Program will respond to eligiable requests with instructions and required forms.

About ERVEBO® booster doses

It's not known how long the initial dose of ERVEBO® protects a patient. Clinicians may be able to request booster doses for eligible individuals who were previously vaccinated (e.g., ≥ 6 months since prior vaccination) under an expanded access IND protocol. Final eligibility decisions for booster doses, including dose interval, will be assessed on a case-by-case basis.

For further details, including healthcare provider responsibilities under this IND program, see Expanded Access Investigational New Drug (IND) Protocol #7298, ERVEBO®.

Requesting ERVEBO® booster doses

Licensed healthcare providers interested in ERVEBO® as a booster for a previously vaccinated patient should:

  1. Review the IND protocol to ensure the patient meets the eligibility criteria.
  2. Send an email to spathvax@cdc.gov with subject line: Request for ERVEBO vaccine booster.
    1. The CDC Ebola Vaccine Program will respond to eligible requests with instructions and required forms. See Sections 5 and 7 and the listed appendices of the IND protocol for further details.